![Lisa Percival](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lisa Percival
General Counsel bei Vividion Therapeutics, Inc.
Aktive Positionen von Lisa Percival
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vividion Therapeutics, Inc.
![]() Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | General Counsel | - | - |
Karriereverlauf von Lisa Percival
Ehemalige bekannte Positionen von Lisa Percival
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LARIMAR THERAPEUTICS, INC. | General Counsel | - | - |
Ausbildung von Lisa Percival
University of Connecticut | Graduate Degree |
Trinity College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Australien | 2 |
Operativ
General Counsel | 2 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sektoral
Consumer Services | 3 |
Commercial Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Vividion Therapeutics, Inc.
![]() Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
Zafgen, Inc.
![]() Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Lisa Percival
- Erfahrung